The Week in Endocrinology Oral Ozempic & Emerging Therapies

Oral Ozempic Launch, Semaglutide for Alcohol Use Disorder (Lancet RCT), and Canada’s First Generic Semaglutide | Week Ending May 8, 2026This short Week in Diabetes and Endocrinology update covers three key developments for the week ending May 8, 2026: the nationwide U.S. launch of Oral Ozempic (rebranded/reformulated oral semaglutide tablets in 1.5, 4, and 9 mg with smaller pill size, same efficacy/safety, and cardiovascular risk-reduction labeling for adults with type 2 diabetes and established cardiovascular disease, plus pricing details and ongoing fasting administration requirements); a Lancet 26-week randomized trial in 108 adults with obesity and moderate-to-severe alcohol use disorder showing once-weekly semaglutide 2.4 mg added to CBT reduced heavy drinking days and total alcohol consumption with substantial weight loss, while noting it is not approved for AUD and was studied only in obese participants; and Health Canada’s approval of Apotex’s Apo-Semaglutide injection as the first Canadian-made generic Ozempic equivalent, signaling shifting global GLP-1 pricing and access.00:00 Weekly Headlines00:24 Oral Ozempic Launch00:59 Dosing Labeling Pricing01:45 Lancet AUD Trial02:29 What It Means Clinically03:02 Limits Next Trials03:33 Canada Generic Semaglutide04:08 Global Access Shift04:34 Wrap Up And Sign Off